Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Population-level distribution and putative immunogenicity of cancer neoepitopes.

BMC cancer - 13 Apr 2018

Wood Mary A, Paralkar Mayur, Paralkar Mihir P, Nguyen Austin, Struck Adam J, Ellrott Kyle, Margolin Adam, Nellore Abhinav, Thompson Reid F

Abstract excerpt

BACKGROUND: Tumor neoantigens are drivers of cancer immunotherapy response; however, current prediction tools produce many candidates requiring further prioritization. Additional filtration criteria and population-level understanding may assist with prioritization. Herein, we show neoepitope immunogenicity is related to measures of peptide novelty and report population-level behavior of these and other metrics....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to Epitope Mapping

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epitopes

Share to Genomics

Share to Immunotherapy

Share to Neoplasms

Share to Peptides

Share to ROC Curve

Source

Open in PubMed Open full text

Identifiers

PMID: 29653567
DOI: 10.1186/s12885-018-4325-6
PMCID: PMC5899330

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Population-level distribution and putative immunogenicity of cancer neoepitopes.PMID 29653567Read ↗

Population-level distribution and putative immunogenicity of cancer neoepitopesSemantic proximity Read ↗

Comprehensive analysis of neoantigens derived from structural variation across whole genomes from 2528 tumors.Semantic proximity Read ↗

Predicting T cell recognition of MHC class I restricted neoepitopesSemantic proximity Read ↗

Best practices for bioinformatic characterization of neoantigens for clinical utility.Semantic proximity Read ↗

Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapySemantic proximity Read ↗

Seq2Neo: A Comprehensive Pipeline for Cancer Neoantigen Immunogenicity PredictionSemantic proximity Read ↗

Advances and challenges in neoantigen prediction for cancer immunotherapySemantic proximity Read ↗

Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and ImmunotherapySemantic proximity Read ↗

Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy.Semantic proximity Read ↗

A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapySemantic proximity Read ↗

INAEME: Integral Neoantigen Analysis with Entirety of Mutational EventsSemantic proximity Read ↗

Integrated modeling to implicate evolving neoantigen-T cell interplays and immunotherapy efficacy in tumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.